Proqr Therapeutics (PRQR) Stock Price, Quote & News

Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Re...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 88 166 7000

Website: www.proqr.com

Address:

Zernikedreef 9, Leiden, Netherlands

anlkrts Jan. 7 at 10:37 PM

$LLY announced they will lay $14 for each share for $VTYX. Realistic way how much you guys think they might pay for $PRQR ??

1 · Reply

DougAfter60 Jan. 7 at 8:03 PM

$PRQR very happy

0 · Reply

FutureInvesting777 Jan. 7 at 6:34 PM

$PRQR as usual operating standard procedure :)

0 · Reply

ehpats Jan. 7 at 2:59 PM

$PRQR 👀

1 · Reply

justfacts1 Jan. 7 at 12:50 PM

$PRQR Eli Lilly and Company currently owns approximately 16% of ProQR Therapeutics' shares

1 · Reply

Longroader Jan. 7 at 7:48 AM

$PRQR $LLY has hundreds of billions free cash flow to deploy from obesity windfall. They will swop in to buy once POC for NTCP is established and platform de-risked.

0 · Reply

ehpats Jan. 6 at 10:30 PM

$PRQR I take it as very positive that lly is willing to take on these small deals (1b) for clinical stage companies. We certainly fit the lly acquisition model perfectly

0 · Reply

anlkrts Jan. 6 at 10:09 PM

$PRQR $VTYX bought out by $LLY. When are they gonna buy out this?

0 · Reply

OfficialStocktwitsUser Jan. 6 at 10:09 PM

$PRQR RSI: 30.53, MACD: -0.0549 Vol: 0.13, MA20: 2.17, MA50: 2.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

dirkfrank Jan. 6 at 6:31 PM

$PRQR c’mon

1 · Reply

ProQR to Participate in 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 7:00 AM EST - 2 months ago

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov 3, 2025, 6:46 PM EST - 2 months ago

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

Oct 20, 2025, 8:00 AM EDT - 2 months ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

Oct 13, 2025, 8:30 AM EDT - 3 months ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

Aug 7, 2025, 7:00 AM EDT - 5 months ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Jul 28, 2025, 8:00 AM EDT - 5 months ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

Jun 26, 2025, 4:30 PM EDT - 6 months ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

May 12, 2025, 8:00 AM EDT - 8 months ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 8, 2025, 7:00 AM EDT - 8 months ago

ProQR Announces First Quarter 2025 Operating and Financial Results

May 2, 2025, 8:00 AM EDT - 8 months ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 1, 2025, 8:00 AM EDT - 8 months ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Apr 14, 2025, 7:00 AM EDT - 9 months ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Mar 13, 2025, 7:00 AM EDT - 10 months ago

ProQR Announces Year End 2024 Operating and Financial Results

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 10, 2024, 4:30 PM EDT - 1 year ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

May 11, 2024, 5:57 PM EDT - 1 year ago

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

May 9, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2024 Operating and Financial Results

Apr 23, 2024, 7:00 AM EDT - 1 year ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 22, 2024, 4:31 PM EDT - 1 year ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 19, 2024, 7:00 AM EDT - 1 year ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Mar 13, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2023 Operating and Financial Results

Jan 19, 2024, 7:00 AM EST - 2 years ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 5, 2024, 7:00 AM EST - 2 years ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Nov 7, 2023, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 6, 2023, 7:00 AM EST - 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Sep 28, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 7, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 2 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 1, 2023, 7:00 AM EDT - 2 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Jul 9, 2023, 6:53 AM EDT - 2 years ago

ProQR: Too Many Failures For Its RNA Technology

Jul 6, 2023, 7:00 AM EDT - 2 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

May 9, 2023, 8:00 AM EDT - 2 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Apr 20, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Upcoming Investor Conferences in April and May

Apr 18, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Mar 29, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Mar 14, 2023, 8:00 AM EDT - 3 years ago

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Mar 7, 2023, 8:00 AM EST - 3 years ago

ProQR to Present at Upcoming Scientific and Industry Conferences

Dec 22, 2022, 9:12 AM EST - 3 years ago

ProQR's stock jumps on expanded RNA deal with Lilly

LLY

Dec 22, 2022, 6:15 AM EST - 3 years ago

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Dec 22, 2022, 6:00 AM EST - 3 years ago

Lilly and ProQR to Expand RNA Editing Collaboration

LLY

Nov 14, 2022, 4:30 PM EST - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

Nov 9, 2022, 7:00 AM EST - 3 years ago

ProQR Announces Third Quarter 2022 Operating and Financial Results

Aug 11, 2022, 7:00 AM EDT - 3 years ago

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

Jun 1, 2022, 7:00 AM EDT - 3 years ago

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

anlkrts Jan. 7 at 10:37 PM

$LLY announced they will lay $14 for each share for $VTYX. Realistic way how much you guys think they might pay for $PRQR ??

1 · Reply

DougAfter60 Jan. 7 at 8:03 PM

$PRQR very happy

0 · Reply

FutureInvesting777 Jan. 7 at 6:34 PM

$PRQR as usual operating standard procedure :)

0 · Reply

ehpats Jan. 7 at 2:59 PM

$PRQR 👀

1 · Reply

justfacts1 Jan. 7 at 12:50 PM

$PRQR Eli Lilly and Company currently owns approximately 16% of ProQR Therapeutics' shares

1 · Reply

Longroader Jan. 7 at 7:48 AM

$PRQR $LLY has hundreds of billions free cash flow to deploy from obesity windfall. They will swop in to buy once POC for NTCP is established and platform de-risked.

0 · Reply

ehpats Jan. 6 at 10:30 PM

$PRQR I take it as very positive that lly is willing to take on these small deals (1b) for clinical stage companies. We certainly fit the lly acquisition model perfectly

0 · Reply

anlkrts Jan. 6 at 10:09 PM

$PRQR $VTYX bought out by $LLY. When are they gonna buy out this?

0 · Reply

OfficialStocktwitsUser Jan. 6 at 10:09 PM

0 · Reply

dirkfrank Jan. 6 at 6:31 PM

$PRQR c’mon

1 · Reply

ehpats Jan. 5 at 10:48 PM

$PRQR obviously we are all waiting on the imminent release of early P1 data. Will be interesting to see if Van Herk makes any statement post data or if lly makes any moves based on the data. Interesting times for Prqr. This is a long time coming. They better get it right. 🤞

0 · Reply

justfacts1 Jan. 5 at 3:04 PM

$PRQR are they still in holiday)

2 · Reply

ehpats Jan. 2 at 3:29 PM

$PRQR well here’s to 2026 being a breakout year for Prqr. 🍺

1 · Reply

justfacts1 Jan. 2 at 3:09 PM

$PRQR phase I?

0 · Reply

SPRKY Dec. 31 at 4:10 PM

$PRQR hmm. Schwab no longer allows me to buy shares online/through their apps. 🤨

3 · Reply

LeftyT Dec. 30 at 9:05 PM

$PRQR Added 500 more today and paid 1.97 for them. Interesting end of year dip.

2 · Reply

ehpats Dec. 30 at 7:22 PM

$PRQR Here’s the exact quote. “and a first-in-human (FIH) Phase 1 study is being initiated in healthy volunteers. Initial safety, tolerability, and PK data for Cohort 1 is expected toward the end of 2025 with target engagement data for all healthy volunteer cohorts in the first half of 2026”

1 · Reply